Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹2,018Cr
Rev Gr TTM
Revenue Growth TTM
10.45%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

SHK
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 4.8 | 1.8 | 10.0 | 22.6 | 8.7 | 11.3 | 19.1 | 15.2 | 10.5 | 23.5 | 2.1 | 7.5 |
| 405 | 355 | 384 | 396 | 424 | 392 | 462 | 479 | 494 | 508 | 501 | 528 |
Operating Profit Operating ProfitCr |
| 14.2 | 16.1 | 15.7 | 16.1 | 17.4 | 16.6 | 14.9 | 11.9 | 12.9 | 12.6 | 9.5 | 9.6 |
Other Income Other IncomeCr | -20 | 1 | 2 | 2 | 1 | -119 | 20 | 0 | 61 | 3 | 1 | 33 |
Interest Expense Interest ExpenseCr | 7 | 10 | 10 | 10 | 10 | 10 | 13 | 14 | 13 | 13 | 14 | 14 |
Depreciation DepreciationCr | 21 | 21 | 22 | 22 | 22 | 22 | 24 | 23 | 25 | 26 | 27 | 27 |
| 19 | 38 | 41 | 46 | 59 | -73 | 64 | 27 | 97 | 37 | 12 | 49 |
| 18 | 11 | 11 | 14 | 24 | 12 | 24 | 10 | -6 | 11 | 3 | 16 |
|
Growth YoY PAT Growth YoY% | -91.7 | 19.8 | 19.5 | 140.5 | 2,858.4 | -412.0 | 32.0 | -45.5 | 206.6 | 129.4 | -77.0 | 86.3 |
| 0.2 | 6.6 | 6.6 | 6.8 | 6.5 | -18.5 | 7.3 | 3.2 | 18.1 | 4.4 | 1.7 | 5.6 |
| 0.2 | 2.0 | 2.2 | 2.4 | 2.5 | -6.3 | 2.9 | 1.3 | 7.4 | 1.9 | 0.7 | 2.4 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 10.7 | 6.0 | 4.1 | 2.2 | 6.8 | 18.6 | 18.3 | 7.8 | 9.2 | 15.3 | 7.6 |
| 718 | 775 | 815 | 863 | 912 | 956 | 1,086 | 1,350 | 1,469 | 1,538 | 1,826 | 2,031 |
Operating Profit Operating ProfitCr |
| 14.1 | 16.2 | 16.9 | 15.5 | 12.7 | 14.2 | 17.8 | 13.7 | 12.9 | 16.5 | 14.0 | 11.2 |
Other Income Other IncomeCr | 25 | 10 | 12 | 13 | 28 | -27 | 36 | 6 | -9 | 6 | -38 | 98 |
Interest Expense Interest ExpenseCr | 19 | 20 | 5 | 4 | 14 | 25 | 17 | 16 | 24 | 40 | 49 | 53 |
Depreciation DepreciationCr | 29 | 30 | 19 | 24 | 31 | 52 | 62 | 72 | 80 | 86 | 95 | 105 |
| 95 | 110 | 153 | 143 | 115 | 54 | 194 | 132 | 104 | 183 | 115 | 195 |
| 24 | 37 | 48 | 51 | 27 | 19 | 50 | -17 | 41 | 59 | 41 | 25 |
|
| | 3.8 | 43.5 | -11.7 | -5.1 | -59.2 | 301.5 | 3.8 | -57.9 | 96.7 | -40.2 | 129.3 |
| 8.4 | 7.9 | 10.7 | 9.1 | 8.4 | 3.2 | 10.9 | 9.6 | 3.7 | 6.7 | 3.5 | 7.4 |
| 5.3 | 5.4 | 7.3 | 6.5 | 6.2 | 2.6 | 10.5 | 10.8 | 4.5 | 8.9 | 5.3 | 12.3 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 132 | 145 | 145 | 145 | 145 | 141 | 141 | 138 | 138 | 138 | 138 | 138 |
| 368 | 571 | 667 | 712 | 719 | 683 | 810 | 875 | 926 | 1,074 | 1,134 | 1,191 |
Current Liabilities Current LiabilitiesCr | 380 | 250 | 247 | 364 | 480 | 575 | 574 | 725 | 709 | 934 | 1,131 | 1,157 |
Non Current Liabilities Non Current LiabilitiesCr | 54 | 41 | 18 | 58 | 91 | 80 | 370 | 478 | 411 | 254 | 281 | 318 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 615 | 710 | 697 | 698 | 770 | 808 | 1,044 | 1,232 | 1,207 | 1,363 | 1,576 | 1,556 |
Non Current Assets Non Current AssetsCr | 328 | 297 | 380 | 581 | 675 | 682 | 854 | 1,065 | 1,016 | 1,039 | 1,109 | 1,249 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 62 | 86 | 102 | 103 | 77 | 205 | 195 | 50 | 197 | 107 | 16 |
Investing Cash Flow Investing Cash FlowCr | -17 | -77 | -104 | -164 | -137 | -40 | -149 | -160 | -103 | -82 | -72 |
Financing Cash Flow Financing Cash FlowCr | -7 | -24 | -16 | 28 | 49 | -196 | 88 | 12 | -175 | 8 | 99 |
|
Free Cash Flow Free Cash FlowCr | 40 | 63 | 64 | -17 | -39 | 205 | 199 | 78 | 149 | 47 | -80 |
| 87.7 | 118.3 | 97.6 | 111.6 | 87.9 | 572.2 | 135.6 | 33.6 | 312.4 | 86.8 | 21.3 |
CFO To EBITDA CFO To EBITDA% | 52.4 | 57.7 | 61.7 | 65.3 | 58.5 | 129.7 | 82.7 | 23.4 | 90.5 | 35.4 | 5.3 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 3,276 | 4,308 | 3,738 | 2,219 | 1,097 | 1,579 | 1,987 | 1,375 | 2,841 | 2,460 |
Price To Earnings Price To Earnings | 0.0 | 44.9 | 41.1 | 39.8 | 25.1 | 30.7 | 10.9 | 13.4 | 22.5 | 23.2 | 33.6 |
Price To Sales Price To Sales | 0.0 | 3.5 | 4.4 | 3.6 | 2.1 | 1.0 | 1.2 | 1.3 | 0.8 | 1.5 | 1.1 |
Price To Book Price To Book | 0.0 | 4.6 | 5.3 | 4.4 | 2.6 | 1.3 | 1.7 | 2.0 | 1.3 | 2.3 | 1.9 |
| 1.2 | 21.8 | 26.0 | 24.5 | 19.0 | 8.7 | 8.3 | 11.9 | 8.9 | 11.2 | 10.8 |
Profitability Ratios Profitability Ratios |
| 44.9 | 44.5 | 45.4 | 44.9 | 43.4 | 43.4 | 43.2 | 40.8 | 40.4 | 44.1 | 43.7 |
| 14.1 | 16.2 | 16.9 | 15.5 | 12.7 | 14.2 | 17.8 | 13.7 | 12.9 | 16.5 | 14.0 |
| 8.4 | 7.9 | 10.7 | 9.1 | 8.4 | 3.2 | 10.9 | 9.6 | 3.7 | 6.7 | 3.5 |
| 15.8 | 16.5 | 18.1 | 14.4 | 10.8 | 6.8 | 14.3 | 8.7 | 7.6 | 11.9 | 7.8 |
| 14.1 | 10.2 | 12.9 | 10.8 | 10.2 | 4.3 | 15.1 | 14.8 | 5.9 | 10.2 | 5.8 |
| 7.5 | 7.3 | 9.7 | 7.2 | 6.1 | 2.4 | 7.6 | 6.5 | 2.8 | 5.2 | 2.8 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
S H Kelkar & Company Ltd (SHK) is India’s largest homegrown Fragrance & Flavour (F&F) company, with over **100 years of industry experience**. The company operates under the **SHK**, **Cobra**, and **Keva** brands, offering a comprehensive portfolio of **fragrances, flavours, natural ingredients, aroma chemicals, and specialty extracts**. It serves a diverse, global client base across **FMCG, personal care, pharmaceuticals, food & beverages, home care, and fine fragrances**.
With a strong presence in **India, Europe, Southeast Asia, and the U.S.**, SHK combines **deep regional insights, advanced R&D, and vertically integrated manufacturing** to deliver customized solutions that align with evolving consumer trends.
---
### **Business Segments & Revenue Mix**
- **Fragrance Segment**: Dominates revenue, contributing **~91%** in FY24–25 (up from ~88% in prior years). Products used in personal care, fabric care, home care, fine fragrances, and industrial applications like ambient scents for automobiles and consumer durables.
- **Flavours Segment**: Accounts for the remaining **~9%** of revenue. Supplies certified (FSSAI, USFDA, Halal) flavors to dairy, beverages, bakery, savory foods, and pharmaceuticals.
- **Global Ingredients**: A rapidly recovering segment benefiting from **supply chain de-risking trends**, especially post-pandemic and due to reduced dependency on Chinese chemical suppliers.
---
### **Strategic Focus & Growth Strategy: '3I' Framework**
SHK’s long-term growth is anchored on the **‘3I’ strategy**:
1. **India** – R&D, backward integration, and domestic leadership hub.
2. **Italy** – Anchors European operations via **Creative Fragrances & Flavours (CFF)** and **Holland Aromatics**, enhancing access to Western Europe.
3. **Indonesia** – Gateway to ASEAN markets with a greenfield manufacturing plant in **Jakarta**, improving regional supply chain resilience and speed-to-market.
This framework supports market expansion, innovation, and integration across geographies.
---
### **Global Presence & Manufacturing Footprint**
- **Manufacturing Facilities**: Five key sites in India (Vapi, Vashivali, Mahad), Italy (Milan), and Indonesia (Jakarta). Total capacity allows for **significant scalability** — Indian plants operate below full utilization (~50–55%) with potential to triple output with minimal capex.
- **In-house Manufacturing**: A key differentiator. SHK owns all core manufacturing, unlike peers relying on outsourcing. This ensures **quality control, IP protection, cost efficiency, and long-term scalability**.
- **Backward Integration**: Invests heavily in securing raw material supply, including cultivation of **Vetiver and Geranium oil** in India via **Keva Aromatics**, reducing reliance on geopolitically sensitive regions like Haiti and China.
---
### **R&D & Innovation Leadership**
SHK distinguishes itself through **technology-led innovation**:
- Operates **seven+ Creation & Development Centres (CDCs)** globally in **India, Singapore, Italy, Germany, Netherlands, UK (Manchester), and Indonesia**.
- Launched new CDCs in **Germany (2024)** and **Manchester, UK (2025)**, with a **fully operational U.S. development center** in New Jersey supporting North American clients.
- The U.S. center, while not a manufacturing hub, enables **faster turnaround and deeper engagement with U.S.-based MNCs** using **tolling or local contract manufacturing**.
- Over the past 5 years:
- Developed **17 proprietary molecules**.
- Filed **20 patent applications**, with **6 commercially exploited** in deodorants and fine fragrances.
- Only Indian-origin F&F company to file patents in **fragrance and novel aroma molecules**.
---
### **Acquisitions & Inorganic Growth**
Strategic acquisitions have strengthened SHK’s global footprint:
- **CFF (Italy)**: Acquired 100% stake in 2020 (~₹223 crore), a premium fine fragrance and fabric care player with strong European distribution.
- **Nova Fragranze (Italy)**: 70% stake acquired in 2021, enhancing presence in high-margin beauty and hair care fragrances.
- **Holland Aromatics (Netherlands)**: Acquired 62% in early 2022, full ownership by 2024 — strengthens **Northern European market access** and positions SHK as a key supplier to MNCs.
- **NuTaste (India)**: Expanded into ready-to-use flavors for **QSR, canteens, and food delivery**, with a focus on **savory seasonings and syrups**.
These acquisitions have created **cross-selling opportunities, operational synergies, and enhanced client engagement in Europe**.
---
### **Client Base & Market Penetration**
- Serves **4,000+ medium to large FMCG companies**, including **Unilever, Danone, Nestlé, Britannia, Mondelez**, and emerging **D2C and e-commerce brands**.
- **>95% repeat business** with **no long-term contracts** — client retention driven by **product quality, IP ownership, and consumer success**.
- Revenue highly diversified:
- **Top 3 customers** account for only ~10% of total revenue.
- Over **90% of business is proprietary**, giving high customer stickiness.
- Actively engaging with **global MNCs**:
- Secured multi-year contracts with a **major global FMCG client**, doubling FY25 order book.
- Became a **pre-qualified vendor** for global tenders; targeting **20% win rate** from a $100M annual opportunity pool.
- Gaining traction in **U.S., Middle East, and Africa**, with dedicated sales offices planned in **UAE**.
---
### **Recent Developments (2025)**
- **New U.S. Development Center**: Fully operational in **New Jersey**, enhancing presence in the **world’s largest F&F market** ($10B+ TAM). Supports U.S. clients with faster innovation cycles and tariff-resilient supply.
- **UK CDC in Manchester**: Complements German CDC, deepening R&D capacity in **Western Europe**, especially UK, France, and MENA.
- **Greenfield Facility in Vanavate**: To be commissioned by **end-2025**, consolidating leased operations, improving efficiency, and reducing working capital.
- **Expansion in Industrial Fragrances**: Growing segment in **automotive accessories and consumer electronics**, with steady growth in India and Asia.
---
### **Market Trends & Strategic Positioning**
- **Consumer Shifts**: Driving demand for **clean-label, natural, premium, and health-oriented** products.
- **Supply Chain Diversification**: Global shift away from China benefits SHK, especially in **Global Ingredients**.
- **Sustainability Initiatives**:
- Developed **Santalol**, a **biosustainable alternative to sandalwood oil** in partnership with BASF/Isobionics.
- Focus on **biodegradable molecules** via **Plant Biotechnology and Microbiology divisions**.
- In-house **safety testing and AI-driven product development** accelerating innovation.